RxDoctor Payments Data

Joel Moore, MD

Internal Medicine · Greenville, NCNPI 1972928703

Payments from drug & device makers

$505in general payments, 2019–2025

Across 27 payments — averaging $18.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tricoast Surgical Solutions LLC$142
  • Novo Nordisk$125
  • Amgen$101
  • Lilly USA, LLC$25
  • AstraZeneca$24
  • AbbVie$22
  • plus $67 from 5 others

What the payments were for

  • Food & beverage$505100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$505 in reported general payments places this provider in the 65th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$376,647
Medicare patients
653
Services billed
13,662

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban119$108,029
OzempicSemaglutide102$106,641
JardianceEmpagliflozin50$49,098
RybelsusSemaglutide25$42,947
LinzessLinaclotide67$42,340
ArexvyRsvpref3 Antigen/As01e/Pf109$33,904
XareltoRivaroxaban22$33,871
JanuviaSitagliptin Phosphate34$30,808
Repatha SureclickEvolocumab32$30,203
TrulicityDulaglutide24$27,274
MounjaroTirzepatide25$26,092
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$25,064
FarxigaDapagliflozin Propanediol18$17,770
Combivent RespimatIpratropium/Albuterol Sulfate24$16,083
WegovySemaglutide11$14,941

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Wegovy$125$164,529138 claims
PfizerEliquis$17$108,029119 claims
Lilly USA, LLCTrulicity, Mounjaro$25$53,36649 claims
AbbVieLinzess$22$42,34067 claims
AstraZenecaFarxiga, Crestor, Symbicort, Pulmicort Flexhaler$24$28,73957 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Greenville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →